IL2 and cancer: On the basis of these studies, Seta Clinic Group started in 1999 the adoptive alpha/beta T cell immune therapy without IL-2 injection, for various types of cancer preferentially in the advanced stage with or without chemo- or radiotherapy, and good responses were observed in some cases without serious side effects [28–31].